SCHEMBL2198394

SCHEMBL2198394

COc1ccc(Cn2ccn(C)c2=[Pt])cc1.Clc1ccc(CN(I)I)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.42
TP53 P04637 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.38
BCL2A1 Q16548 2/20 0.38
LPO P22079 2/20 0.36
ALDH1A1 P00352 2/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
NPBWR1 P48145 1/20 0.36
CNR2 P34972 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
MDM4 O15151 1/20 0.35
MDM2 Q00987 1/20 0.35
KCNA3 P22001 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALOX15 P16050 1/20 0.35
CMA1 P23946 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2194976 0.91 SIGMAR1 (0.44) MAPTTP53LMNALPOCYP1A2
SCHEMBL2195985 0.89 MAPT (0.38) MAPTTP53SMN1; SMN2LMNALPO
SCHEMBL2193843 0.89 MET (0.43) MAPTTP53SMN1; SMN2LMNALPO
SCHEMBL2194970 0.89 LPO (0.52) MAPTTP53SMN1; SMN2LMNALPO
SCHEMBL2195285 0.86 LMNA (0.39) MAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL2194667 0.86 BACE1 (0.39) MAPTTP53LMNAALDH1A1NPBWR1
SCHEMBL2197666 0.85 MAPT (0.40) MAPTTP53SMN1; SMN2LMNALPO
SCHEMBL15085525 0.84 MAPT (0.49) MAPTTP53SMN1; SMN2LMNALPO
SCHEMBL2195738 0.82 OPRL1 (0.40) MAPTSMN1; SMN2ALDH1A1KCNA3KDM4E
SCHEMBL2195234 0.82 LSS (0.33) MAPTTP53ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MAPT 4712/4885TP53 1327/4885SMN1; SMN2 4069/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 MAPT 4712/4885TP53 1327/4885SMN1; SMN2 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.